2Cattral MS,Langnas AN,Wisecarver JL,et al.Survival of graft-versus-host disease in a liver transplantation recipientt.Transplantation,1994,27,57(8):1271-1274.
4Billingham RE.The biology of graft-versus-host reactions.Harvey Lectures,1966,62:21-78.
5Klingebiel T.GVHD:overview on pathophysiology,incidence,clinical and biological features.Bone Marrow Transplant,1998,21 Suppl 2:S45-49.
6Martin PJ.Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in marrow transplantation from unrelated donors compared with related donors.Bone Marrow Transplant,1991,8(3):217-223.
7Nikolic B.Th1 and Th2 mediate acute graft-host disease,each with distinct end-organ targets.Clininvest,2000,105(9):1289-1298.
8Lopez C,Kirkpatrick D,Sorell M,et al.Association between pre-transplant natural kill and graft-versus-host disease after stem-cell transplantation.Lancet,1979,24:2(8152):1103-1107.
9Levine JE.Implications of TNF-αin the pathogenesis and management of GVHD.Int J Hematol,2011,93(5):571577.
10Bostrom L,Ringden O,Gratama JW,et al.A role of herpes virus serology for the development ofacute graft-versus-host disease.Leukaemia Working Party of the European Group for Bone Marrow Transplantation.Bone Marrow Transplant,1990,5:321-326.
4Dormady SP, Bashayan O, Dougherty R, et al. Immortalized multipotential mesenchymal cells and the hematopoietic microenvironment[J]. Hematother Stem Cell Res, 2001, 10:125-140
5Noort WA, Kruisselbrink AB, Anker PS, et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34+cells in NOD/SCID mice[J]. Exp Hematol, 2002, 30: 870-878
6Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo[J]. Exp Hematol, 2002, 30:42-48
7Le Blanc K, Tammik C, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex[J]. Scand J Immunol, 2003, 57:11-20
9Slavin S,Nagler A,Naparstek E,et al.Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease[J].Blood,1998,91:756-763.
10Nash RA,Storb R.Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation:GVHD and GVL[J].Curr Opin Immunol,1996,8:674-680.
